Revision history of "Development of a biotechnology drug by developing an innovative monoclonal antibody of the IgG1 subclass with reduced glycoforms to the reference medicine – against the EGFR" (Q78895)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 October 2024

  • curprev 05:5505:55, 13 October 2024DG Regio talk contribs 92,684 bytes −47 Changed label, description and/or aliases in pt
  • curprev 05:5505:55, 13 October 2024DG Regio talk contribs 92,731 bytes −189 Set a claim value: summary (P836): Número de referência do programa de ajuda: SA.41471(2015/X) Objetivo do auxílio público: Artigo 25.o do Regulamento (CE) n.o 651/2014, de 17 de junho de 2014, que declara certos tipos de auxílio compatíveis com o mercado interno, em aplicação dos artigos 107.o e 108.o do Tratado (JO L EU L 187/1 de 26.6.2014). O objeto do projeto é a realização de trabalhos de I & D destinados ao desenvolvimento do MabionEGFR, um anticorpo monoclonal inovador da sub...

22 March 2024

12 January 2024

11 June 2023

24 May 2023

2 March 2023

  • curprev 22:2322:23, 2 March 2023DG Regio talk contribs 90,165 bytes +1,949 Changed label, description and/or aliases in lv, ro, fr, da, it, et, ga, sk, cs, lt, de, bg, sv, es, hr, fi, hu, sl, pt, nl, el, mt, and other parts

25 October 2022

20 October 2022

25 July 2022

  • curprev 21:1621:16, 25 July 2022DG Regio talk contribs 86,550 bytes +55,661 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, sl, cs, lt, lv, bg, hu, ga, sv, et,

19 January 2022

15 January 2022

16 December 2021

7 December 2021

30 November 2021

  • curprev 14:2614:26, 30 November 2021DG Regio talk contribs 18,277 bytes +2,715 Created claim: summary (P836): Reference_Aid_programme: SA.41471(2015/X) But_public_aid: Article 25 du règlement (CE) no 651/2014 du 17 juin 2014 déclarant certaines catégories d’aides compatibles avec le marché intérieur en application des articles 107 et 108 du traité (JO URZ. EU L 187/1 du 26.6.2014). L’objectif du projet est de réaliser des travaux de R & D visant à développer le MabionEGFR — un anticorps monoclonal innovant de la sous-classe IgG1, spécifiquement dirigé c...
  • curprev 14:2614:26, 30 November 2021DG Regio talk contribs 15,562 bytes +310 Changed label, description and/or aliases in fr: translated_label

29 October 2020

14 October 2020

  • curprev 10:3210:32, 14 October 2020DG Regio talk contribs 15,692 bytes +239 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 10:3210:32, 14 October 2020DG Regio talk contribs 15,453 bytes −236 Changed label, description and/or aliases in 1 language: remove_english_label
  • curprev 10:3210:32, 14 October 2020DG Regio talk contribs 15,689 bytes +2,723 Created claim: summary (P836): Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The subject of the project is to carry out R & D works aimed at the development of MabionEGFR, an innovative monoclonal antibody of the IgG1 subc...
  • curprev 10:3210:32, 14 October 2020DG Regio talk contribs 12,966 bytes −2,364 Removed claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The project involves carrying out the R & D work towards the development of MabionEGFR, an innovative monoclonal antibody to the IgG1 subclass, targeted spec...

25 September 2020

23 September 2020

15 July 2020

9 June 2020

6 June 2020

26 March 2020

4 March 2020

  • curprev 08:5308:53, 4 March 2020DG Regio talk contribs 13,617 bytes +2,364 Created claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The project involves carrying out the R & D work towards the development of MabionEGFR, an innovative monoclonal antibody to the IgG1 subclass, targeted specif...

18 February 2020

8 February 2020

31 January 2020

13 January 2020